RVL Pharmaceuticals plc (NASDAQ: RVLP) to Attend H.C. Wainwright 25th Annual Global Investment Conference and Discuss UPNEEQ(R) for Treating Acquired Blepharoptosis
RVL Pharmaceuticals' CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year's H.C. Wainwright Annual Global Investment Conference in New York City The company will discuss UPNEEQ(R) and its use as the first non-surgical treatment option approved by the FDA for acquired blepharoptosis RVL Pharmaceuticals plans to continue marketing to medical aesthetics providers and will launch a direct-to-consumer campaign later this year The medical aesthetics market was valued at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027 RVL Pharmaceuticals (NASDAQ:…